MACROGENICS INC — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
MacroGenics reported interim Phase 1 results for MGC026 (B7-H3-targeted antibody-drug conjugate) accepted for poster presentation at ESMO Congress October 2026. The SCCHN cohort met pre-specified Stage 1 response threshold and is enrolling Stage 2 (target 40 patients). As of July 8, 2026, 74 total patients enrolled across dose escalation and cohort expansion; no interstitial lung disease or ocular toxicity reported; anti-tumor activity observed across indications. Recommended dose: 7.5 mg/kg q3W.
Why this rating
Clinical progress on lead asset is strategically important for $74M biotech; data acceptance and advancement to Stage 2 validate compound but remain early-stage Phase 1. Modest positive catalyst but no commercial revenue or transformational event.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.